Altre lingue Cara Therapeutics, Inc.

Azioni

CARA

US1407551092

Tempo reale stimato Cboe BZX Altri mercati azionari 16:14:55 30/04/2024			Variaz. 5gg	Var. 1 gen.
0,73 ^USD	-3,38%		+5,36%	+0,27%

22/03	Cara Therapeutics, Inc. annuncia le dimissioni della Dr.ssa Joana Goncalves da Chief Medical Officer, con effetto dal 16 aprile 2024	CI
06/03	CARA THERAPEUTICS, INC. : Canaccord Genuity conferma il rating Buy	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference	02/04
Cara Therapeutics, Inc. Announces Resignation of Dr. Joana Goncalves as Chief Medical Officer, Effective April 16, 2024	22/03
Cara Therapeutics to Host Notalgia Paresthetica Virtual KOL Event on Wednesday, March 27, 2024	08/03
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024	07/03
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024	07/03
Cara: Q4 Earnings Snapshot	04/03
Cara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	04/03
Earnings Flash (CARA) CARA THERAPEUTICS Reports Q4 Revenue $3M, vs. Street Est of $9.1M	04/03
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results	04/03
North American Morning Briefing : Stock Futures -2-	04/03
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024	12/02
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024	12/02
Cara Therapeutics to Cut Workforce Up to 50%, Halt Work on Chronic Kidney Disease; Chief Scientific Officer to Exit	22/01
Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026	22/01
Cara Therapeutics, Inc. Prioritizes Late-Stage Notalgia Paresthetica Program	22/01
Cara Therapeutics, Inc. Announces Frédérique Menzaghi Departs as Chief Scientific Officer and SVP of Research & Development, Effective February 2, 2024	22/01
Top Midday Decliners	18/12
Cara Therapeutics, Inc. Announces Outcome from Dose- Finding Part A of the KIND 1 Study Evaluating Oral Difelikefalin for Mod Moderate-To-Severe Pruritus in Patients with Atopic Dermatitis	18/12
Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis	18/12
Cara Therapeutics, Inc.(NasdaqGM:CARA) dropped from NASDAQ Biotechnology Index	15/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Cara Therapeutics, Inc.

Azioni

CARA

US1407551092

Altre lingue

Filtri